| EQR |
Report |
Q2 2026 normalized FFO per share |
IN-LINE |
pred ~$1.02 vs. cons $1.01 |
MEDIUM |
| EQR |
Report |
Q2 2026 same-store revenue growth |
BEAT |
pred ~2.7% vs. cons 2.6% |
MEDIUM |
| EQR |
Report |
Q2 2026 same-store NOI growth |
BEAT |
pred ~2.4% vs. cons 2.2% |
MEDIUM |
| EQR |
Guide |
FY2026 normalized FFO per share |
LOWER |
guide ~$4.08 vs. cons $4.10 (FY2026) |
MEDIUM |
| EQR |
Guide |
FY2026 same-store NOI growth |
LOWER |
guide ~1.7% vs. cons 1.8% (FY2026) |
LOW |
| EQR |
Guide |
Q3 2026 normalized FFO per share |
LOWER |
guide ~$1.03 vs. cons $1.04 (Q3 2026) |
LOW |
| EQR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.8% |
— |
LOW |
| EQR |
Return |
5-day cumulative residual |
-0.2% (FADE) |
Operating KPIs should support an initial gain, but FY2026 guidance of ~$4.08 versus consensus of $4.10 implies approximately $2.06 of second-half NFFO after the predicted first half, below roughly $2.09 embedded in consensus; that out-period cut should pull estimates lower and fade the headline reaction. |
MEDIUM |